IDH2 and central nervous system cancer: Heterozygous gain-of-function mutations in IDH1/2 (isocitrate dehydrogenase (NADP(+) 1/2; IDH) is traditionally a hallmark of a subset of gliomas associated with favorable patient outcomes (Parsons et al., 2008; Yan et al., 2009).